|
FDA approval of Regeneron’s hearing loss gene ... - BioSpace
Approved Thursday via the FDA's Commissioner’s National Priority Voucher program, Otarmeni is the first gene therapy for hearing loss—and the first treatment to target an underlying cause of the condition.
The FDA gives the green light to the first gene therapy for ...
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss.
The FDA gives the green light to the first gene therapy for ...
The gene provides instructions to make the otoferlin protein, which is necessary for hair cells in the inner ear to transmit sound to the brain. Most of the patients began to hear for the first time within weeks, with the quality of their hearing improving over the following months, according to Regeneron.
The FDA gives the green light to the first gene therapy for ...
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. The decision , while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the quest to treat hearing loss.
The FDA gives the green light to the first gene therapy for ...
The FDA gives the green light to the first gene therapy for deafness The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. NPR
FDA Gives Green Light To the First Gene Therapy For Deafness
An anonymous reader quotes a report from NPR: The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf. The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as a milestone in the...
The FDA gives the green light to the first gene therapy for ...
The treatment, developed by Regeneron Pharmaceuticals, is for a very rare form of deafness. But it represents a medical milestone. from NPR Topics: News https://ift.tt/TRupIQj Labels: NPR Topics: News
|
FIRE101 Fire Jobs 